Dabur India Limited has received an administrative warning letter from the Securities and Exchange Board of India (SEBI). The company is alleged to have violated provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically concerning a delay in disclosing a warning letter received from the US FDA. Dabur India stated it is committed to compliance and will address the concerns.
SEBI Issues Administrative Warning to Dabur India
Dabur India Limited has been issued an administrative warning letter by the Securities and Exchange Board of India (SEBI) concerning alleged violations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication, dated November 6, 2026, highlights a delay in making a disclosure related to a warning letter received from the US Food and Drug Administration (USFDA) on July 24, 2026.
Details of Alleged Non-Compliance
The warning letter from SEBI, specifically referencing Regulation 30 and sub-para 20 of Para A Part A Schedule III of the SEBI (LODR) Regulations, alleges that Dabur India failed to promptly disclose the USFDA warning letter. This administrative action is intended to caution the company against future lapses in disclosure timelines. The SEBI letter advises the company and its Board of Directors to be careful and avoid recurrence of such issues.
Company’s Stance and Next Steps
Dabur India has provided the requisite information as per Regulation 30 of the SEBI Listing Regulations, along with the SEBI warning letter, as annexures to its communication to the stock exchanges. The company has asserted its consistent compliance with SEBI Listing Regulations and stated that it will take necessary steps to address the concerns raised in the SEBI letter. The intimation is also available on the company’s website.
No Financial Impact
According to the company’s disclosure, there is no anticipated impact on the financial operations or other activities of Dabur India due to this administrative warning letter.
Source: BSE
